secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0000879407-25-000019
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome
--------------------------------------------------------------------------------

- REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.
- Phase 3 PALISADE study showed 80% median triglyceride reduction vs 17% placebo and lower acute pancreatitis incidence.
- REDEMPLO is first FDA-approved siRNA medicine for FCS, self-administered quarterly at home.
- Approximately 6,500 people in the U.S. live with genetic or clinical FCS.
- Arrowhead's first FDA-approved medicine marks transition to a commercial-stage company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/0000879407-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/arwr-20251118.htm
  HTML page:      https://secwatch.observer/filing/0000879407-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer